Paroxysmal Supraventricular Tachycardia (PSVT) Market: by Type (AVNRT, AVRT, PAT, WPW) Diagnosis (EPS, Echocardiogram, Holter Monitor, Event Monitor) Treatment (Physical Maneuvers, medications), End-User (Hospitals & Clinics) - Forecast Till 2032

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type

6.1 Introduction

6.2 AV Nodal Re-Entrant Tachycardia (AVNRT)

6.2.1 Market Estimates & Forecast, 2023–2030

6.3 AV Reciprocating Tachycardia (AVRT),

6.3.1 Market Estimates & Forecast, 2023–2030

6.4 Paroxysmal Atrial Tachycardia (PAT),

6.4.1 Market Estimates & Forecast, 2023–2030

6.5 Wolff-Parkinson-White Syndrome (WPW)

6.5.1 Market Estimates & Forecast, 2023–2030

Chapter 7. Global Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis

7.1 Introduction

7.2 Electrophysiology Study (EPS)

7.2.1 Market Estimates & Forecast, 2023–2030

7.3 Stress Test

7.3.1 Market Estimates & Forecast, 2023–2030

7.4 Cardiac Catheterization

7.4.1 Market Estimates & Forecast, 2023–2030

7.5 Coronary Angiography

7.5.1 Market Estimates & Forecast, 2023–2030

7.6 Electrocardiogram (ECG)

7.6.1 Market Estimates & Forecast, 2023–2030

7.7 Echocardiogram

7.7.1 Market Estimates & Forecast, 2023–2030

7.8 Holter Monitor

7.8.1 Market Estimates & Forecast, 2023–2030

7.9 Event Monitor

7.9.1 Market Estimates & Forecast, 2023–2030

7.10 Implantable Monitor

7.10.1 Market Estimates & Forecast, 2023–2030

7.11 Lab Tests

7.11.1 Market Estimates & Forecast, 2023–2030

7.11.2 Blood Test

7.11.2.1 Market Estimates & Forecast, 2023–2030

7.11.3 Urine Test

7.11.3.1 Market Estimates & Forecast, 2023–2030

7.11.4 Others

7.12 Others

Chapter 8. Global Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment

8.1 Introduction

8.2 Physical Maneuvers

8.2.1 Market Estimates & Forecast, 2023–2030

8.3 Medications

8.3.1 Market Estimates & Forecast, 2023–2030

8.3.2 Calcium Channel Blockers

8.3.2.1 Market Estimates & Forecast, 2023–2030

8.3.2.2 Diltiazem

8.3.2.2.1 Market Estimates & Forecast, 2023–2030

8.3.2.3 Verapamil

8.3.2.3.1 Market Estimates & Forecast, 2023–2030

8.3.2.4 Others

8.3.2.4.1 Market Estimates & Forecast, 2023–2030

8.3.2.5 Diltiazem

8.3.2.5.1 Market Estimates & Forecast, 2023–2030

8.3.3 Antiarrhythmic Medication

8.3.3.1 Market Estimates & Forecast, 2023–2030

8.3.3.2 Sotalol

8.3.3.2.1 Market Estimates & Forecast, 2023–2030

8.3.3.3 Amiodarone

8.3.3.3.1 Market Estimates & Forecast, 2023–2030

8.3.3.4 Amiodarone

8.3.3.4.1 Market Estimates & Forecast, 2023–2030

8.3.3.5 Flecainide

8.3.3.5.1 Market Estimates & Forecast, 2023–2030

8.3.3.6 Propafenone

8.3.3.6.1 Market Estimates & Forecast, 2023–2030

8.3.3.7 Adenosine

8.3.3.7.1 Market Estimates & Forecast, 2023–2030

8.3.4 Beta Blockers

8.3.4.1 Market Estimates & Forecast, 2023–2030

8.3.5 Others

8.4 Catheter Ablation

8.4.1 Market Estimates & Forecast, 2023–2030

8.5 Pacemaker

8.5.1 Market Estimates & Forecast, 2023–2030

8.6 Cardioversion

8.6.1 Market Estimates & Forecast, 2023–2030

Chapter 9. Global Paroxysmal Supraventricular Tachycardia (PSVT) Market, By End-User

9.1 Introduction

9.2 Hospitals & Clinics

9.2.1 Market Estimates & Forecast, 2023–2030

9.3 Diagnostic Centers

9.3.1 Market Estimates & Forecast, 2023–2030

9.4 Medical Research Centers

9.4.1 Market Estimates & Forecast, 2023–2030

9.5 Others

Chapter .10 Global Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest Of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic Of Korea

10.4.6 Rest Of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest Of The Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12 Company Profiles

12.1 GlaxoSmithKline PLC

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Sanofi SA

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Pfizer Inc.

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Novartis International AG

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Teva Pharmaceutical Industries Ltd.

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial Overview

12.5.4 Key Developments

12.6 Medtronic, Inc.

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Glenmark Pharmaceuticals

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 St. Jude Medical, Inc.

12.8.1 Company Overview

12.8.2 Product/Business Segment Overview

12.8.3 Financial Overview

12.8.4 Key Development

12.8.5 SWOT Analysis

12.9 Boston Scientific Corporation

12.9.1 Company Overview

12.9.2 Product Overview

12.9.3 Financial Overview

12.9.4 Key Developments

12.10 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs Of The Market

13.2 Key Companies To Watch

13.3 Prediction Of The Pharmaceutical Industry

Chapter 14 Appendix

LIST OF TABLES

Table 1 Paroxysmal Supraventricular Tachycardia (PSVT) Industry Synopsis, 2023–2030

Table 2 Paroxysmal Supraventricular Tachycardia (PSVT) Market Estimates & Forecast, 2023–2030, (USD Million)

Table 3 Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Region, 2023–2030, (USD Million)

Table 4 Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2023–2030, (USD Million)

Table 5 Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2023–2030, (USD Million)

Table 6 Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2023–2030, (USD Million)

Table 7 North America Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2023–2030, (USD Million)

Table 8 North America Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2023–2030, (USD Million)

Table 9 North America Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2023–2030, (USD Million)

Table 10 U.S. Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2023–2030, (USD Million)

Table 11 U.S. Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2023–2030, (USD Million)

Table 12 U.S. Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2023–2030, (USD Million)

Table 13 Canada Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2023–2030, (USD Million)

Table 14 Canada Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2023–2030, (USD Million)

Table 15 Canada Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2023–2030, (USD Million)

Table 16 South America Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2023–2030, (USD Million)

Table 17 South America Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2023–2030, (USD Million)

Table 18 South America Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2023–2030, (USD Million)

Table 19 Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2023–2030, (USD Million)

Table 20 Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2023–2030, (USD Million)

Table 21 Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2023–2030, (USD Million)

Table 22 Western Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2023–2030, (USD Million)

Table 23 Western Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2023–2030, (USD Million)

Table 24 Western Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2023–2030, (USD Million)

Table 25 Eastern Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2023–2030, (USD Million)

Table 26 Eastern Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2023–2030, (USD Million)

Table 27 Eastern Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2023–2030, (USD Million)

Table 28 Asia Pacific Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2023–2030, (USD Million)

Table 29 Asia Pacific Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2023–2030, (USD Million)

Table 30 Asia Pacific Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2023–2030, (USD Million)

Table 31 Middle East & Africa Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2023–2030, (USD Million)

Table 32 Middle East & Africa Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2023–2030, (USD Million)

Table 33 Middle East & Africa Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2023–2030, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation For Paroxysmal Supraventricular Tachycardia (PSVT) Market

Figure 3 Segmentation Market Dynamics For Paroxysmal Supraventricular Tachycardia (PSVT) Market

Figure 4 Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Type 2023

Figure 5 Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Diagnosis 2023

Figure 6 Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Treatment, 2023

Figure 7 Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Region, 2023

Figure 8 North America Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Country, 2023

Figure 9 Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Country, 2023

Figure 10 Asia Pacific Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Country, 2023

Figure 11 Middle East & Africa Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Country, 2023

Figure 12 Global Paroxysmal Supraventricular Tachycardia (PSVT) Market: Company Share Analysis, 2023 (%)

Figure 13 GLAXOSMITHKLINE PLC: Key Financials

Figure 14 GLAXOSMITHKLINE PLC: Segmental Revenue

Figure 15 GLAXOSMITHKLINE PLC: Geographical Revenue

Figure 16 Sanofi SA: Key Financials

Figure 17 Sanofi SA: Segmental Revenue

Figure 18 Sanofi SA: Geographical Revenue

Figure 19 Pfizer Inc.: Key Financials

Figure 20 Pfizer Inc.: Segmental Revenue

Figure 21 Pfizer Inc.: Geographical Revenue

Figure 22 Novartis International AG: Key Financials

Figure 23 Novartis International AG: Segmental Revenue

Figure 24 Novartis International AG: Geographical Revenue

Figure 25 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 26 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 27 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 28 Medtronic, Inc..: Key Financials

Figure 29 Medtronic, Inc.: Segmental Revenue

Figure 30 Medtronic, Inc.: Geographical Revenue

Figure 31 Glenmark Pharmaceuticals: Key Financials

Figure 32 Glenmark Pharmaceuticals: Segmental Revenue

Figure 33 Glenmark Pharmaceuticals: Geographical Revenue

Figure 34 St. Jude Medical, Inc.: Key Financials

Figure 35 St. Jude Medical, Inc.: Segmental Revenue

Figure 36 St. Jude Medical, Inc.: Geographical Revenue

Figure 37 Boston Scientific Corporation: Key Financials

Figure 38 Boston Scientific Corporation: Segmental Revenue

Figure 39 Boston Scientific Corporation: Geographical Revenue